WO2019022219A1 - Noradrenalin secretion promoting amino acid composition - Google Patents

Noradrenalin secretion promoting amino acid composition Download PDF

Info

Publication number
WO2019022219A1
WO2019022219A1 PCT/JP2018/028197 JP2018028197W WO2019022219A1 WO 2019022219 A1 WO2019022219 A1 WO 2019022219A1 JP 2018028197 W JP2018028197 W JP 2018028197W WO 2019022219 A1 WO2019022219 A1 WO 2019022219A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
food
acid composition
noradrenaline
present
Prior art date
Application number
PCT/JP2018/028197
Other languages
French (fr)
Japanese (ja)
Inventor
亮一 田川
啓輔 上田
三本木　千秋
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Publication of WO2019022219A1 publication Critical patent/WO2019022219A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Definitions

  • the present invention relates to an amino acid composition for promoting the secretion of noradrenaline, and a food, beverage and medicine containing the amino acid composition.
  • an amino acid composition containing 18 amino acids similar to the composition of the amino acid unit constituting casein promotes fat burning, improves endurance, prevents or reduces fatigue caused by exercise, reduces or relieves fatigue, anti-obesity, anti-stress
  • the composition (VAAM) is composed of 17 kinds of amino acids contained in the saliva secreted by the wasp's larva (US Pat. It is known that replenishment, fatigue recovery, and lactic acid production can be regulated (Patent Document 2). Furthermore, it is also known that glutamine is added to VAAM to improve anoxic movement associated with heavy load (Patent Document 3).
  • VAAM is known to have an adrenaline and noradrenaline secretagogue action, and by this action, blood pressure increase, blood glucose level maintenance, exercise capacity improvement, tension maintenance, lipolysis of obese people It is said to be useful as an agent for promoting and preventing hyperlipidemia (Patent Document 4).
  • Patent Document 4 Although the mechanism of secretion of adrenalin and noradrenaline in VAAM is not well understood, it is presumed that tyrosine and phenylalanine in VAAM are synthesized to adrenalin and noradrenaline in adrenal gland and secreted in blood.
  • using amino acid compositions to promote secretion of adrenalin and / or noradrenaline has not been sufficiently studied.
  • an object of the present invention is to provide a novel amino acid composition capable of promoting the secretion of adrenalin and / or noradrenaline.
  • the present inventors focused on arginine, valine and serine in earnest studies to solve the above problems, and an amino acid composition containing only these three amino acids has high noradrenaline secretagogue action, and further, The inventors have found that they have a tendency to promote the secretion of adrenalin, and as a result of further studies, they have completed the present invention.
  • an amino acid composition for promoting secretion of noradrenaline which comprises arginine, valine and serine.
  • a food, beverage or medicine for promoting the secretion of noradrenaline comprising an effective amount of the amino acid composition according to any one of the above [1] to [4].
  • the food, beverage or medicine according to the above-mentioned [5] which comprises an ineffective amount of an amino acid other than arginine, valine and serine.
  • the food, beverage or medicine according to any one of the above [5] to [7] which is packed in a container.
  • an amino acid composition having an effect of increasing blood noradrenaline concentration during exercise and a food, a drink, and a medicine containing the amino acid composition.
  • the amino acid compositions of the present invention have a tendency to increase blood adrenaline levels.
  • both adrenalin and noradrenaline are adrenal medullary hormones and activate sympathetic nerves, according to the present invention, actions such as catabolism promotion, blood pressure elevation, brain awakening and the like can be expected.
  • blood adrenaline concentration and / or blood noradrenaline concentration during exercise are increased, and exercise performance is improved.
  • FIG. 1 is an explanatory view showing an outline of a test system.
  • FIG. 2 is a graph showing the measured blood adrenaline concentration.
  • FIG. 3 is a graph showing the measured blood noradrenaline concentration.
  • FIG. 4 is a correlation distribution diagram between blood noradrenaline concentration 5 minutes after Wingate test and peak power in Wingate test.
  • the amino acid composition for promoting noradrenaline secretion of the present invention consists of three types, arginine, valine and serine.
  • the weight ratio of arginine, valine and serine is, in one aspect, 50 to 70: 25 to 50: 0.1 to 15 and in another aspect 10 to 28: 7 to 22: 1, preferably 15-18: 11-14: 1. With this weight ratio, a further secretion promoting effect is exerted.
  • the amino acid composition of the present invention is, in one aspect, packaged in a container, preferably packaged in an edible container.
  • the edible container includes a capsule for preparation and the like.
  • the amino acid composition packaged in the container can be added as it is to foods, beverages, and pharmaceuticals.
  • the amino acid composition of the present invention can be used by being added to foods, beverages or pharmaceuticals in an amount effective to exert a secretion promoting effect.
  • the food or beverage to which the effective amount of the amino acid composition is added has a composition different from that of the food or beverage which is naturally present.
  • Such an effective amount can be determined as appropriate by those skilled in the art.
  • the total weight of arginine, valine and serine is 500 mg to 10000 mg, preferably 1500 mg to 5000 mg, particularly preferably 2500 mg to 3500 mg.
  • the food, beverage or medicament of the present invention may contain amino acids other than arginine, valine and serine.
  • amino acids other than arginine, valine and serine even if they are known to promote the secretion of adrenalin and / or noradrenaline, for example, an amount which is not effective to exert a secretion promoting effect (ineffective amount) May be included.
  • ineffective amounts can be determined as appropriate by those skilled in the art.
  • the amino acids used in the present invention may be any of L-form, D-form and DL-form, but preferably L-form and DL-form, more preferably L-form. It is. Furthermore, not only free amino acids but also amino acid salts can be used as the amino acids used in the present invention.
  • the amino acid salt is not particularly limited as long as it is a food, beverage or pharmaceutically acceptable amino acid salt, and examples thereof include acid addition salts of amino acids and salts with bases.
  • Examples of the acid which forms a food-acceptable salt of an amino acid used in the present invention include inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid and phosphoric acid; acetic acid, lactic acid, citric acid, tartaric acid, maleic acid and fumar And acids and organic acids such as monomethyl sulfuric acid.
  • inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid and phosphoric acid
  • acetic acid lactic acid, citric acid, tartaric acid, maleic acid and fumar And acids
  • organic acids such as monomethyl sulfuric acid.
  • a food-acceptable salt base for example, inorganic bases such as sodium, potassium, calcium and ammonia, ethylenediamine, propylenediamine, ethanolamine, monoalkylethanolamine, dialkylethanolamine, diethanolamine, triethanolamine and the like
  • organic bases of The salt of the amino acid used in the present invention may be a hydrate (hydrated salt), and such hydrates include, for example, 1 to 6 hydrates.
  • the amino acids used in the present invention may be any of those extracted and purified from animals and plants containing these, microorganisms and the like, and those obtained by chemical synthesis, fermentation, and genetic recombination. Moreover, a commercial item can also be used.
  • the amino acids used in the present invention are preferably single items and high in purity. For example, an amino acid having a purity higher than that defined in the "Food Additives Official Declaration" is used. Moreover, as these amino acids, those in the form of their physiologically acceptable salts can also be used.
  • the above amino acids may be mixed to produce the amino acid composition of the present invention. Further, in the case of producing a solution, it may be mixed with distilled water, ethanol or the like and dissolved.
  • the food, beverage or medicament of the present invention may further contain an active ingredient for promoting the secretion of adrenaline and / or noradrenaline which is not an amino acid. Examples of such an active ingredient include caffeine and catechin.
  • ingredients which can be contained in the food, beverage or medicament of the present invention are not particularly limited as long as they can be taken (administered) into the body, but ingredients usually incorporated in medicine and / or food and drink, for example, Vitamin B1, vitamin B2, vitamin B6, vitamins such as pantothenic acid, CoQ10, carnitine, vitamin-like substances such as ⁇ -lipoic acid, minerals such as iron and zinc, glucose, fructose, galactose, mannose sucrose, maltose, lactose Such as sugars, citric acid, tartaric acid, ascorbic acid, malic acid, acetic acid, oxalic acid, phosphoric acid, lactic acid, lactic acid, butyric acid, succinic acid, fumaric acid and organic acids such as gluconic acid, caffeine, theobromine, theanine, catechins etc Polyphenols can be blended.
  • amino acid components such as sodium glutamate and taurine, sucralose, neotame, acesulfame potassium, thaumatin, stevia extract, licorice extract, lacanka extract, saccharin, saccharin sodium, glycyrrhizin, disodium glycyrrhizinate, trisodium glycyrrhizinate, Sweeteners such as dihydrochalcone, stevioside, rebaudioside A, minerals such as zinc, selenium, iron and copper, trehalose, oligosaccharides, saccharides such as rare sugars, lactic acid bacteria, bifidobacteria, propionibacteria etc.
  • amino acid components such as sodium glutamate and taurine, sucralose, neotame, acesulfame potassium, thaumatin, stevia extract, licorice extract, lacanka extract, saccharin, sacchar
  • Microorganisms and their cultures royal jelly, collagen, ceramide, glucosamine, astaxanthin, polyphenols and other existing functional materials, flavors, pH adjusters, excipients, acidulants such as citric acid, colorants, Agent, may be formulated and preservatives.
  • the intake (administration) form of the amino acid composition of the present invention is not limited as long as it can be taken (administered) into the body, but for example, tablets, coated tablets, capsules, granules, powders, solutions, syrups Oral administration by emulsion, etc. is preferred.
  • These various preparations are pharmaceuticals such as excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, solubilizers, suspending agents, coating agents, etc. in the amino acid composition according to the present invention according to a conventional method. It can be formulated using known adjuvants which can be generally used in the formulation art of
  • the food and drink of the present invention includes, in one embodiment, for example, food and drink materials, food additives and the like, food and drink (food for specified health use, health indication food such as functional indication food, nutrition function food, etc., nutrition support It can also be provided as food, other health food, supplements).
  • the food and drink of the present invention are, for example, beverages, dairy products such as yogurt, jelly products, ice creams, frozen desserts, cookies, products such as gums, powder products, granular products, sheet products, capsule products , Tablet products, solid processed food of confectionery, and the like.
  • the food and drink according to the present invention is not limited to a pharmaceutical composition, and may be a solution, a suspension, an emulsion, a powder, a solid molded product, or the like as long as it can be orally ingested.
  • dairy products such as milk drinks, yogurts, lactic acid bacteria drinks, fermented milks, ice creams, creams, cheeses; soft drinks, fruit juices, vegetable drinks, soy milk drinks, coffee drinks, tea drinks , Beverages such as jelly drinks, cocoa, smoothies, powder drinks and sports powder drinks, fortified powder drinks, powder foods, powder soup, steamed bread, concentrated drinks, alcoholic beverages and other beverages; bread, pasta, noodles, Cake mix, fried flour, flour products such as bread crumbs; chocolate, gum, sweet potato, cookies, gummy, snacks, sweets such as Japanese sweets, jellies, puddings and other sweets; processed seasonings, flavored seasonings, cooking mixes, etc.
  • the other ingredients are not particularly limited, but the food and drink may be water, protein, carbohydrate, lipid, vitamins, minerals, organic acid, Organic bases, fruit juice, flavors and the like can be used as ingredients.
  • proteins include whole milk powder, skimmed milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, egg protein, animal protein such as meat protein, hydrolysates of these, butter, whey mineral, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose etc
  • various milk-derived components of Examples thereof include saccharides, modified starches (dextrin, soluble starch, British starch, oxidized starch, starch esters, starch ethers and the like), dietary fiber and the like.
  • lipids examples include animal fats and oils such as lard and fish oil, fractionated oils thereof, hydrogenated oils, transesterified oils and the like; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Vegetable oils and fats such as hydrogenated oils and transesterified oils may be mentioned.
  • vitamins for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline And folic acid and the like
  • minerals for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like
  • examples of the organic acid include malic acid, citric acid, lactic acid and tartaric acid. These components can be used in combination of 2 or more types, and you may use the foodstuff which contains a synthetic product and / or these abundantly.
  • the food, beverage, and pharmaceutical product of the present invention may, in one aspect, be packaged in a container, which may be selected from plastic, paper, metal, pottery or composite materials thereof. It can be in the form of a container packed in these containers. That is, a container-packed food / drink product, a container-packed pharmaceutical containing the amino acid composition of the present invention can be exemplified.
  • the container may be covered with a plastic shrink film, a light shielding film (for example, a metal foil layer film, a black or dark ink applied film, or the container or the film may be used in combination of two or more types. From the viewpoint of taste deterioration and decomposition (reduction) by light transmission and oxygen transmission, it is preferable to combine a light-shielding container or film.
  • the amino acid composition or food and drink of the present invention is in unit package form per serving, and contains arginine, valine and serine in the unit package form.
  • "consisting of" unit packaging form per serving means that the intake per serving is previously determined, and for example, as a food and drink that can orally ingest a specific amount, not only general food but also It means forms such as beverages (drinks etc.), health supplements, health functional foods, supplements and the like.
  • unit packaging form per serving for example, in the case of liquid beverages, gel-like, paste-like or paste-like jelly, powder-like, granular, capsule-like or block-like solid food etc.
  • a form that can specify a specific amount (dose) in packaging containers such as metal cans, glass bottles (such as bottles), plastic containers (such as plastic bottles), packs, pouches, film containers, paper boxes, etc.
  • a dose can be specified on a packaging container, a home page or the like to specify a specific amount.
  • the daily intake of the amino acid composition or the food and drink of the present invention is individually determined based on exercise, age, sex, body weight, dietary condition and the like.
  • the amino acid composition of the present invention and foods, beverages or medicines containing it can be expected to improve exercise performance, so people without sports habits, sports enthusiasts, athletes, obese reserve forces, obesity, patients and animals with metabolic syndrome It is preferably used for race animals and the like.
  • the amino acid composition or food / drink product of the present invention is preferably labeled with an indication that it is effective in enhancing exercise performance by promoting secretion of noradrenaline, preferably sympathetic nerve activation, concentration Improvement, prevention of fatigue, improvement of fatigue, reduction of fatigue, reduction of fatigue, enhancement of glucose metabolism, increase in lipid metabolism, degradation of fat, improvement of lipid metabolism, improvement of exercise performance, for example, improvement of muscle strength, Ability to improve instantaneous power, stamina, endurance, feel lighter, maintain strength until the second half of the exercise, maintain concentration, reduce body fatigue, reduce sagging, reduce tightness, firmly train Can enjoy sports (exercise), can perform ideal performance, can move easily, and exceeds the usual performance limits Or it may be displayed attached indicating the Runado effective.
  • the display of the present invention is not particularly limited as long as it is attached in relation to the amino acid composition for promoting norepinephrine secretion, for example, an amino acid composition for promoting noradrenaline secretion, food, beverage, medicine
  • the container, the packaging material, or the package insert that is contained may be provided with a display, an advertisement, etc. that the composition is effective.
  • the display of the present invention is, for example, a display, advertisement, etc. in which the composition is effective for storage media such as flyers, brochures, pops, catalogs, posters, books, books, DVDs, etc. It may be attached.
  • the same content as the display of the present invention can be transmitted to a third party by reproduction from a verbal and / or recorded / recorded recording medium for the purpose of business talk and / or promotion.
  • amino acids for promoting secretion of noradrenaline according to the present invention foods, beverages, and medicaments may be mixed using the above amino acids. Moreover, what is necessary is just to mix and melt
  • Example 1 Preparation of amino acid composition (encapsulated) A mixture of L-arginine, L-valine and L-serine was added to Cellulose White Capsule No. 00 (Matsuya Co., Ltd.) so that L-arginine 1800 mg, L-valine 1100 mg, L-serine 100 mg in 5 capsules. It filled and the encapsulated amino acid composition (Example 1) was prepared. L-arginine, L-valine and L-serine are manufactured by Kyowa Hakko Bio Co., Ltd.
  • Example 2 Exercise Test An exercise test was conducted when the amino acid composition of the present invention was ingested. The outline of the test system is shown in FIG. Test food (encapsulated amino acid composition of Example 1) and control food (capsulated amino acid composition of Example 1) and control food (not distinguishable from appearance to maintain double-blindness, cellulose white capsule similar to test food 00) No. 5 (manufactured by Matsuya Co., Ltd.) containing 3000 mg of dextrin (Comparative Example 1)) was used.
  • the subjects were randomly divided into two groups using age and weight at screening as indicators, and a double blind crossover crossover test was conducted.
  • Group 1 9 performs the test food intake test first, and then performs the control food intake test at intervals of 6 days or more, and group 2 (10) performs the control food intake test first Then, at intervals of 6 days or more, test food intake test was conducted.
  • the test food was consumed twice daily at a dose of 3000 mg for 3 days, and the exercise test was performed on the 3rd day (FIG. 1).
  • the dinner on the day before the exercise test was taken as a diet, and carbohydrate jelly was ingested on the day of the exercise test, with a fasting time of 12.5 to 15.5 hours.
  • One hour after ingestion of the sugar jelly the first intake of the test food is taken, and 10 minutes after the first intake of the test food by a bicycle ergometer (Aerobike (registered trademark) 75 XL III (manufactured by Konami Sports Life Co., Ltd.) for 10 minutes Warm up was performed, and the following endurance exercise was performed 30 minutes after the first intake of the test food.
  • the endurance exercise was performed twice across the interval of the movement of 45 minutes at 50% VO 2peak strength 15 minutes to perform a second intake of the test food during the first 50% VO 2peak intensity exercise ends.
  • the Wingate test is a representative method for evaluating anoxic exercise capacity, and in this experiment, it was performed under the condition of performing full power pedaling at a load of 7.5% of body weight for 30 seconds.
  • the above exercise was all carried out using a bicycle ergometer (warming up, endurance exercise: aerobic bike (registered trademark) 75 XL III (manufactured by Konami Sports Life Co., Ltd.), Wingate test: Powermax VIII (manufactured by Konami Sports Life Co., Ltd.) )It was used).
  • Blood adrenaline concentration and blood noradrenaline concentration were measured by HPLC (HLC-725CAII, Tosoh Corporation). The measurement results of blood adrenaline concentration are shown in FIG. 2, and the measurement results of blood noradrenaline concentration are shown in FIG.
  • Example 1 was ingested, compared to Comparative Example 1, blood adrenaline and blood noradrenaline concentrations during exercise increased. In particular, (at the end of the first 50% VO 2peak intensity exercise) blood noradrenaline concentrations S3, S4 (at the end of endurance exercise), remained at significantly higher during the S5 (Wingate test completion after 5 minutes).
  • Example 1 When the Example 1 was ingested, the peak power in the Wingate test tended to be higher than in the Comparative Example 1. There was a positive correlation between the blood noradrenaline concentration of S5 (5 minutes after completion of Wingate test) and the performance of Wingate test (FIG. 4). When Example 1 was ingested, compared with the case of ingesting Comparative Example 1, blood adrenaline concentration and blood noradrenaline concentration became higher, and exercise performance was improved.
  • Example 3 Storage of amino acid composition 1800 mg of L-arginine, 1100 mg of L-valine and 100 mg of L-serine were filled in Cellulose White Capsule No. 00 to prepare a capsuled amino acid composition and filled in an aluminum pouch container. The amino acid-containing composition in the capsule after 2 weeks of storage at room temperature was retained without decomposition (reduction).
  • the amino acid composition of the present invention has the effect of promoting the secretion of noradrenaline, tends to promote the secretion of adrenalin, and can improve exercise performance and motivation for exercise.
  • people with less exercise can practice exercise routinely, and food for exercise enthusiasts and athletes to maintain and improve exercise performance can be designed.
  • it leads to the extension of the healthy life span of the Japanese, and as a result, it is possible to greatly contribute to society by reducing medical expenses and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The purpose of the present invention is to provide a novel amino acid composition which can promote secretion of adrenaline and/or noradrenalin. The present invention relates to a noradrenaline secretion promoting amino acid composition formed from arginine, valine and serine, specifically to a noradrenaline secretion promoting amino acid composition in which the weight ratio of arginine, valine and serine is 50-70 : 25-50 : 0.1-15, and further relates to a noradrenaline secretion promoting food, beverage or drug that contains the amino acid composition in an effective amount.

Description

ノルアドレナリンの分泌促進用アミノ酸組成物Amino acid composition for promoting noradrenaline secretion
　本発明は、ノルアドレナリンの分泌促進用アミノ酸組成物ならびに該アミノ酸組成物を含む食品、飲料および医薬品に関する。 The present invention relates to an amino acid composition for promoting the secretion of noradrenaline, and a food, beverage and medicine containing the amino acid composition.
　アミノ酸組成物と、運動機能や運動に伴う疲労感との関係について多くの検討がされてきた。例えば、カゼインを構成するアミノ酸単位の組成と近似させた１８種類のアミノ酸を含むアミノ酸組成物が、脂肪燃焼の促進、持久力の向上、運動による疲労の予防、軽減または回復、抗肥満、抗ストレスなどの作用を有することや（特許文献１）、スズメバチの幼虫が分泌するだ液中に含まれる１７種類のアミノ酸で構成される組成物（ＶＡＡＭ）が、筋力持続、滋養強壮、輸液用途、栄養補給、疲労回復、乳酸生成調節できることが知られている（特許文献２）。さらにＶＡＡＭに、グルタミンを加えることによって、強い負荷に伴う無酸素運動を向上させることも知られている（特許文献３）。 Many studies have been made on the relationship between the amino acid composition and the feeling of fatigue associated with motor function and exercise. For example, an amino acid composition containing 18 amino acids similar to the composition of the amino acid unit constituting casein promotes fat burning, improves endurance, prevents or reduces fatigue caused by exercise, reduces or relieves fatigue, anti-obesity, anti-stress The composition (VAAM) is composed of 17 kinds of amino acids contained in the saliva secreted by the wasp's larva (US Pat. It is known that replenishment, fatigue recovery, and lactic acid production can be regulated (Patent Document 2). Furthermore, it is also known that glutamine is added to VAAM to improve anoxic movement associated with heavy load (Patent Document 3).
　ＶＡＡＭは、アドレナリンおよびノルアドレナリン分泌促進作用を有していることが知られており、かかる作用により、血圧の亢進、血中血糖量の維持、運動能の向上、緊張の維持、肥満者の脂肪分解促進および予防、高脂血症の治療剤として有用であるとされている（特許文献４）。ＶＡＡＭのアドレナリンおよびノルアドレナリンの分泌メカニズムについては十分に解明されていないものの、ＶＡＡＭ中の、チロシンやフェニルアラニンが副腎でアドレナリンおよびノルアドレナリンに合成され、血中に分泌されるものと推定されている。
　これまで、アミノ酸組成物を用いて、アドレナリンおよび／またはノルアドレナリンの分泌を促進させることについて十分に検討されていなかった。 VAAM is known to have an adrenaline and noradrenaline secretagogue action, and by this action, blood pressure increase, blood glucose level maintenance, exercise capacity improvement, tension maintenance, lipolysis of obese people It is said to be useful as an agent for promoting and preventing hyperlipidemia (Patent Document 4). Although the mechanism of secretion of adrenalin and noradrenaline in VAAM is not well understood, it is presumed that tyrosine and phenylalanine in VAAM are synthesized to adrenalin and noradrenaline in adrenal gland and secreted in blood.
Heretofore, using amino acid compositions to promote secretion of adrenalin and / or noradrenaline has not been sufficiently studied.
国際公開第２００８／１０５３６８号International Publication No. 2008/105368 特許第２５１８６９２号公報Patent No. 2518692 gazette 特許第４５２８９２５号公報Patent No. 4528925 gazette 特開平６－３３６４３２号公報Unexamined-Japanese-Patent No. 6-336432
　したがって、本発明の課題は、アドレナリンおよび／またはノルアドレナリンの分泌を促進することができる新たなアミノ酸組成物を提供することにある。 Therefore, an object of the present invention is to provide a novel amino acid composition capable of promoting the secretion of adrenalin and / or noradrenaline.
　本発明者は、前記の課題を解決するために鋭意研究する中で、アルギニン、バリン、およびセリンに着目し、これら僅か３つのアミノ酸を含むアミノ酸組成物が高いノルアドレナリン分泌促進作用を有し、さらにアドレナリンの分泌を促進する傾向を有することを見出し、さらに研究を進めた結果、本発明を完成するに至った。 The present inventors focused on arginine, valine and serine in earnest studies to solve the above problems, and an amino acid composition containing only these three amino acids has high noradrenaline secretagogue action, and further, The inventors have found that they have a tendency to promote the secretion of adrenalin, and as a result of further studies, they have completed the present invention.
　すなわち、本発明は、以下の発明に関する。
［１］アルギニン、バリンおよびセリンからなるノルアドレナリンの分泌促進用アミノ酸組成物。
［２］アルギニン、バリンおよびセリンの重量比が、５０～７０：２５～５０：０．１～１５である、前記［１］に記載のアミノ酸組成物。
［３］アルギニン、バリンおよびセリンの重量比が、１０～２８：７～２２：１である、前記［１］に記載のアミノ酸組成物。
［４］可食性容器に詰められてなる、前記［１］～［３］のいずれか一項に記載のアミノ酸組成物。
［５］前記［１］～［４］のいずれか一項に記載のアミノ酸組成物を有効量で含む、ノルアドレナリンの分泌促進用の食品、飲料または医薬品。
［６］アルギニン、バリンおよびセリン以外のアミノ酸を非有効量で含む、前記［５］に記載の食品、飲料または医薬品。
［７］さらに、アミノ酸ではないアドレナリンおよびノルアドレナリンの分泌促進用の有効成分を含む、前記［５］または［６］に記載の食品、飲料または医薬品。
［８］容器に詰められてなる、前記［５］～［７］のいずれか一項に記載の食品、飲料または医薬品。
［９］アルギニン、バリンおよびセリンを混合することを含む、前記［１］～［４］のいずれか一項に記載のアミノ酸組成物または前記［５］～［８］のいずれか一項に記載の食品、飲料または医薬品の製造方法。 That is, the present invention relates to the following inventions.
[1] An amino acid composition for promoting secretion of noradrenaline, which comprises arginine, valine and serine.
[2] The amino acid composition according to the above [1], wherein the weight ratio of arginine, valine and serine is 50-70: 25-50: 0.1-15.
[3] The amino acid composition according to the above [1], wherein the weight ratio of arginine, valine and serine is 10 to 28: 7 to 22: 1.
[4] The amino acid composition according to any one of the above [1] to [3], which is packed in an edible container.
[5] A food, beverage or medicine for promoting the secretion of noradrenaline, comprising an effective amount of the amino acid composition according to any one of the above [1] to [4].
[6] The food, beverage or medicine according to the above-mentioned [5], which comprises an ineffective amount of an amino acid other than arginine, valine and serine.
[7] The food, beverage or medicine according to the above [5] or [6], further comprising an active ingredient for promoting secretion of adrenaline and noradrenaline which are not amino acids.
[8] The food, beverage or medicine according to any one of the above [5] to [7], which is packed in a container.
[9] The amino acid composition according to any one of the above [1] to [4], which comprises mixing arginine, valine and serine, or any one of the above [5] to [8] Of food, beverages or medicines.
　本発明によれば、運動中の血中ノルアドレナリン濃度の上昇効果を有するアミノ酸組成物、該アミノ酸組成物を含む食品、飲料、医薬品を提供することができる。さらに本発明のアミノ酸組成物は、血中アドレナリン濃度を上昇させる傾向を有する。とくにアドレナリン、ノルアドレナリンはともに副腎髄質ホルモンであり、交感神経を活性化させることから、本発明により、異化促進、血圧上昇、脳の覚醒などの作用が期待できる。さらに、運動前に本発明のアミノ酸組成物などを摂取することで、運動中の血中アドレナリン濃度および／または血中ノルアドレナリン濃度が上昇し、運動パフォーマンスが向上する。 According to the present invention, it is possible to provide an amino acid composition having an effect of increasing blood noradrenaline concentration during exercise, and a food, a drink, and a medicine containing the amino acid composition. Furthermore, the amino acid compositions of the present invention have a tendency to increase blood adrenaline levels. In particular, since both adrenalin and noradrenaline are adrenal medullary hormones and activate sympathetic nerves, according to the present invention, actions such as catabolism promotion, blood pressure elevation, brain awakening and the like can be expected. Furthermore, by taking the amino acid composition and the like of the present invention before exercise, blood adrenaline concentration and / or blood noradrenaline concentration during exercise are increased, and exercise performance is improved.
図１は、試験系の概要を示す説明図である。FIG. 1 is an explanatory view showing an outline of a test system. 図２は、測定した血中アドレナリン濃度を示すグラフである。FIG. 2 is a graph showing the measured blood adrenaline concentration. 図３は、測定した血中ノルアドレナリン濃度を示すグラフである。FIG. 3 is a graph showing the measured blood noradrenaline concentration. 図４は、Wingate test５分後の血中ノルアドレナリン濃度と、Wingate testにおけるピークパワーとの相関分布図である。FIG. 4 is a correlation distribution diagram between blood noradrenaline concentration 5 minutes after Wingate test and peak power in Wingate test.
　本発明のノルアドレナリンの分泌促進用アミノ酸組成物は、アルギニン、バリンおよびセリンの３種類からなる。アルギニン、バリンおよびセリンの重量比は、一態様において、５０～７０：２５～５０：０．１～１５であり、他の態様において、１０～２８：７～２２：１であり、好ましくは、１５～１８：１１～１４：１である。かかる重量比にすることによって、より一層の分泌促進効果を奏する。 The amino acid composition for promoting noradrenaline secretion of the present invention consists of three types, arginine, valine and serine. The weight ratio of arginine, valine and serine is, in one aspect, 50 to 70: 25 to 50: 0.1 to 15 and in another aspect 10 to 28: 7 to 22: 1, preferably 15-18: 11-14: 1. With this weight ratio, a further secretion promoting effect is exerted.
　本発明のアミノ酸組成物は、一態様において、容器に詰められており、好ましくは、可食性容器に詰められている。可食性容器とは、製剤用のカプセルなどが挙げられる。可食性容器を用いることによって、容器に詰められたアミノ酸組成物を、そのまま食品、飲料、医薬品に添加することができる。 The amino acid composition of the present invention is, in one aspect, packaged in a container, preferably packaged in an edible container. The edible container includes a capsule for preparation and the like. By using an edible container, the amino acid composition packaged in the container can be added as it is to foods, beverages, and pharmaceuticals.
　本発明のアミノ酸組成物は、分泌促進効果を奏するのに有効な量で、食品、飲料または医薬品に添加して用いることができる。有効量のアミノ酸組成物が添加された食品または飲料は、自然界にそのまま存在する食品または飲料とは異なる組成になる。かかる有効量は、当業者が適宜決定することができるが、例えば、アルギニン、バリンおよびセリンの総重量が、５００ｍｇ～１００００ｍｇ、好ましくは、１５００ｍｇ～５０００ｍｇ、とくに好ましくは、２５００ｍｇ～３５００ｍｇである。 The amino acid composition of the present invention can be used by being added to foods, beverages or pharmaceuticals in an amount effective to exert a secretion promoting effect. The food or beverage to which the effective amount of the amino acid composition is added has a composition different from that of the food or beverage which is naturally present. Such an effective amount can be determined as appropriate by those skilled in the art. For example, the total weight of arginine, valine and serine is 500 mg to 10000 mg, preferably 1500 mg to 5000 mg, particularly preferably 2500 mg to 3500 mg.
　本発明の食品、飲料または医薬品は、アルギニン、バリンおよびセリン以外のアミノ酸を含んでいてもよい。
　本発明において、アルギニン、バリンおよびセリン以外のアミノ酸は、仮にアドレナリンおよび／またはノルアドレナリンの分泌促進用として知られていたとしても、例えば、分泌促進効果を奏するのに有効ではない量（非有効量）で含まれていてもよい。かかる非有効量は、当業者が適宜決定することができる。 The food, beverage or medicament of the present invention may contain amino acids other than arginine, valine and serine.
In the present invention, amino acids other than arginine, valine and serine, even if they are known to promote the secretion of adrenalin and / or noradrenaline, for example, an amount which is not effective to exert a secretion promoting effect (ineffective amount) May be included. Such ineffective amounts can be determined as appropriate by those skilled in the art.
　本発明において用いられるアミノ酸は、それぞれＬ－体、Ｄ－体、ＤＬ－体のいずれであっても使用可能であるが、好ましくはＬ－体、ＤＬ－体であり、さらに好ましくはＬ－体である。また、本発明において用いられるアミノ酸は、それぞれ遊離体のみならず、アミノ酸塩も使用できる。アミノ酸塩では、食品、飲料または医薬品として許容されるアミノ酸塩であればとくに制限されないが、例えば、アミノ酸の酸付加塩や塩基との塩などが挙げられる。 The amino acids used in the present invention may be any of L-form, D-form and DL-form, but preferably L-form and DL-form, more preferably L-form. It is. Furthermore, not only free amino acids but also amino acid salts can be used as the amino acids used in the present invention. The amino acid salt is not particularly limited as long as it is a food, beverage or pharmaceutically acceptable amino acid salt, and examples thereof include acid addition salts of amino acids and salts with bases.
　本発明において用いられるアミノ酸の食品として許容される塩を形成する酸としては、例えば、塩酸、臭化水素、硫酸、リン酸などの無機酸；酢酸、乳酸、クエン酸、酒石酸、マレイン酸、フマル酸、モノメチル硫酸などの有機酸などが挙げられる。また、食品として許容される塩の塩基としては、例えば、ナトリウム、カリウム、カルシウム、アンモニアなどの無機塩基やエチレンジアミン、プロピレンジアミン、エタノールアミン、モノアルキルエタノールアミン、ジアルキルエタノールアミン、ジエタノールアミン、トリエタノールアミンなどの有機塩基が挙げられる。
　本発明において用いられるアミノ酸の塩は、水和物（含水塩）であってもよく、かかる水和物としては、例えば１～６水和物が挙げられる。 Examples of the acid which forms a food-acceptable salt of an amino acid used in the present invention include inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid and phosphoric acid; acetic acid, lactic acid, citric acid, tartaric acid, maleic acid and fumar And acids and organic acids such as monomethyl sulfuric acid. In addition, as a food-acceptable salt base, for example, inorganic bases such as sodium, potassium, calcium and ammonia, ethylenediamine, propylenediamine, ethanolamine, monoalkylethanolamine, dialkylethanolamine, diethanolamine, triethanolamine and the like And organic bases of
The salt of the amino acid used in the present invention may be a hydrate (hydrated salt), and such hydrates include, for example, 1 to 6 hydrates.
　本発明において用いられるアミノ酸は、これらを含有する動植物、微生物などから抽出し精製したものや、化学合成法、発酵法、遺伝子組換法によって得られるもののいずれを使ってもよい。また、市販品も使うことができる。
　本発明において用いられるアミノ酸は、各々、単品で高純度のものが好ましい。例えば、「食品添加物公定書」に規定する純度以上のアミノ酸を使用する。また、これらのアミノ酸としては、その生理学的に許容し得る塩の形態のものも使用可能である。 The amino acids used in the present invention may be any of those extracted and purified from animals and plants containing these, microorganisms and the like, and those obtained by chemical synthesis, fermentation, and genetic recombination. Moreover, a commercial item can also be used.
The amino acids used in the present invention are preferably single items and high in purity. For example, an amino acid having a purity higher than that defined in the "Food Additives Official Declaration" is used. Moreover, as these amino acids, those in the form of their physiologically acceptable salts can also be used.
　本発明のアミノ酸組成物を製造するにあたって、上記アミノ酸を混合すればよい。また溶液を製造する場合には、これを蒸留水、エタノールなどに混合して溶解すればよい。
　本発明の食品、飲料または医薬品は、さらに、アミノ酸ではないアドレナリンおよび／またはノルアドレナリンの分泌促進用の有効成分を含んでいてもよい。このような有効成分としては、例えば、カフェインやカテキンなどが挙げられる。 The above amino acids may be mixed to produce the amino acid composition of the present invention. Further, in the case of producing a solution, it may be mixed with distilled water, ethanol or the like and dissolved.
The food, beverage or medicament of the present invention may further contain an active ingredient for promoting the secretion of adrenaline and / or noradrenaline which is not an amino acid. Examples of such an active ingredient include caffeine and catechin.
　本発明の食品、飲料または医薬品に含まれ得る成分としては、体内に摂取（投与）できるものであれば特段の制限はないが、通常、医薬品および／または飲食品に配合される成分、例えば、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、パントテン酸などのビタミン、ＣｏＱ１０、カルニチン、α－リポ酸などのビタミン様物質、鉄、亜鉛などのミネラル類、グルコース、フルクトース、ガラクトース、マンノースショ糖、麦芽糖、乳糖などの糖類、クエン酸、酒石酸、アスコルビン酸、リンゴ酸、酢酸、シュウ酸、リン酸、乳酸、酪酸、コハク酸、フマル酸およびグルコン酸などの有機酸、カフェイン、テオブロミン、テアニン、カテキンなどのポリフェノール類などを配合することができる。 The ingredients which can be contained in the food, beverage or medicament of the present invention are not particularly limited as long as they can be taken (administered) into the body, but ingredients usually incorporated in medicine and / or food and drink, for example, Vitamin B1, vitamin B2, vitamin B6, vitamins such as pantothenic acid, CoQ10, carnitine, vitamin-like substances such as α-lipoic acid, minerals such as iron and zinc, glucose, fructose, galactose, mannose sucrose, maltose, lactose Such as sugars, citric acid, tartaric acid, ascorbic acid, malic acid, acetic acid, oxalic acid, phosphoric acid, lactic acid, lactic acid, butyric acid, succinic acid, fumaric acid and organic acids such as gluconic acid, caffeine, theobromine, theanine, catechins etc Polyphenols can be blended.
　また、例えば、グルタミン酸ナトリウム、タウリンなどのアミノ酸成分、スクラロース、ネオテーム、アセスルファムカリウム、ソーマチン、ステビア抽出物、カンゾウ抽出物、ラカンカ抽出物、サッカリン、サッカリンナトリウム、グリチルリチン、グリチルリチン酸二ナトリウム、グリチルリチン酸三ナトリウム、ジヒドロカルコン、ステビオサイド、レバウディオサイドＡなどの甘味料、亜鉛、セレン、鉄、銅などのミネラル、トレハロース、オリゴ糖、希少糖などの糖質、乳酸菌、ビフィズス菌、プロピオン酸菌などの有用な微生物やその培養物、ローヤルゼリー、コラーゲン、セラミド、グルコサミン、アスタキサンチン、ポリフェノールなどの既存の機能性素材、香料、ｐＨ調整剤、賦形剤、クエン酸などの酸味料、着色料、乳化剤、保存料などを配合することができる。 Also, for example, amino acid components such as sodium glutamate and taurine, sucralose, neotame, acesulfame potassium, thaumatin, stevia extract, licorice extract, lacanka extract, saccharin, saccharin sodium, glycyrrhizin, disodium glycyrrhizinate, trisodium glycyrrhizinate, Sweeteners such as dihydrochalcone, stevioside, rebaudioside A, minerals such as zinc, selenium, iron and copper, trehalose, oligosaccharides, saccharides such as rare sugars, lactic acid bacteria, bifidobacteria, propionibacteria etc. Microorganisms and their cultures, royal jelly, collagen, ceramide, glucosamine, astaxanthin, polyphenols and other existing functional materials, flavors, pH adjusters, excipients, acidulants such as citric acid, colorants, Agent, may be formulated and preservatives.
　本発明のアミノ酸組成物の摂取（投与）形態としては、体内に摂取（投与）できれば、その方法には制限はないが、例えば錠剤、被覆錠剤、カプセル剤、顆粒剤、散剤、溶液、シロップ剤、乳液などによる経口投与が好ましい。これらの各種製剤は、常法に従って本発明によるアミノ酸組成物に賦形剤、結合剤、崩壊剤、滑沢剤、着色剤、矯味矯臭剤、溶解補助剤、懸濁剤、コーティング剤などの医薬の製剤技術分野において、通常使用しうる既知の補助剤を用いて製剤化することができる。 The intake (administration) form of the amino acid composition of the present invention is not limited as long as it can be taken (administered) into the body, but for example, tablets, coated tablets, capsules, granules, powders, solutions, syrups Oral administration by emulsion, etc. is preferred. These various preparations are pharmaceuticals such as excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, solubilizers, suspending agents, coating agents, etc. in the amino acid composition according to the present invention according to a conventional method. It can be formulated using known adjuvants which can be generally used in the formulation art of
　本発明の飲食品は、一態様において、例えば、飲食品用素材および食品添加物などを加えて、飲食品（特定保健用食品、機能性表示食品、栄養機能食品などの保健機能食品、栄養補助食品、その他の健康食品、サプリメントを含む）として提供することもできる。 The food and drink of the present invention includes, in one embodiment, for example, food and drink materials, food additives and the like, food and drink (food for specified health use, health indication food such as functional indication food, nutrition function food, etc., nutrition support It can also be provided as food, other health food, supplements).
　本発明の飲食品は、例えば、飲料、ヨーグルトなどの乳製品、ゼリー状製品、アイスクリーム類、氷菓、クッキー、ガム状などの製品、粉末状製品、顆粒状製品、シート状製品、カプセル状製品、タブレット状製品、菓子の固形状の加工食品などとすることができる。 The food and drink of the present invention are, for example, beverages, dairy products such as yogurt, jelly products, ice creams, frozen desserts, cookies, products such as gums, powder products, granular products, sheet products, capsule products , Tablet products, solid processed food of confectionery, and the like.
　本発明の飲食品とは、医薬組成物以外のものであって、溶液、懸濁液、乳濁液、粉末、固体成形物など、経口摂取可能な形態であればよく、とくに限定されない。具体的には、例えば、乳飲料、ヨーグルト類、乳酸菌飲料、発酵乳、アイスクリーム類、クリーム類、チーズ類などの乳製品；清涼飲料、果汁飲料、野菜飲料、豆乳飲料、コーヒー飲料、茶飲料、ゼリー飲料、ココア、スムージーなどの粉末飲料やスポーツ粉末飲料、栄養強化の粉末飲料、粉末食品、粉末スープ、蒸しパンのもと、濃縮飲料、アルコール飲料などの飲料類；パン、パスタ、麺、ケーキミックス、唐揚げ粉、パン粉などの小麦粉製品；チョコレート、ガム、飴、クッキー、グミ、スナック、和菓子、ゼリー、プリンなどのデザート菓子などの菓子類；加工調味料、風味調味料、調理ミックスなどの調味料；カレー、パスタソース、ポトフ、シチュー、和風食品のレトルト食品；加工油脂、バター、マーガリン、スプレッド、マヨネーズなどの油脂類；フリーズドライ食品などの即席食品類；農産缶詰、ジャム・マーマレード類、煮豆、シリアル、雑炊などの農産加工品；水産加工品；畜産加工品；ピッツア、ドリア、グラタン、惣菜、フライなど冷凍食品；流動食、とろみ調整食品さらには動物の飼料、タブレットなどが挙げられる。 The food and drink according to the present invention is not limited to a pharmaceutical composition, and may be a solution, a suspension, an emulsion, a powder, a solid molded product, or the like as long as it can be orally ingested. Specifically, for example, dairy products such as milk drinks, yogurts, lactic acid bacteria drinks, fermented milks, ice creams, creams, cheeses; soft drinks, fruit juices, vegetable drinks, soy milk drinks, coffee drinks, tea drinks , Beverages such as jelly drinks, cocoa, smoothies, powder drinks and sports powder drinks, fortified powder drinks, powder foods, powder soup, steamed bread, concentrated drinks, alcoholic beverages and other beverages; bread, pasta, noodles, Cake mix, fried flour, flour products such as bread crumbs; chocolate, gum, sweet potato, cookies, gummy, snacks, sweets such as Japanese sweets, jellies, puddings and other sweets; processed seasonings, flavored seasonings, cooking mixes, etc. Curry, pasta sauce, pot-au-feu, stew, Japanese-style food retort food; processed fats and oils, butter, margarine, spreads, ma Fats and oils such as naise; Instant foods such as freeze-dried foods; Agricultural processed products such as canned agricultural products, jams and marmalades, boiled beans, cereals and sierras; Fisheries processed products; Livestock processed products; Pizza, doria, gratin, sugar beet, Frozen food such as frying; liquid food, thickened food, animal feed, tablets and the like.
　本発明のアミノ酸組成物を飲食品に使用する場合に、その他の成分についても、とくに限定されないが、前記飲食品には、水、タンパク質、糖質、脂質、ビタミン類、ミネラル類、有機酸、有機塩基、果汁、フレーバー類などを成分として使用することができる。タンパク質としては、例えば全脂粉乳、脱脂粉乳、部分脱脂粉乳、カゼイン、ホエイ粉、ホエイタンパク質、ホエイタンパク質濃縮物、ホエイタンパク質分離物、α－カゼイン、β－カゼイン、κ－カゼイン、β－ラクトグロブリン、α－ラクトアルブミン、ラクトフェリン、大豆タンパク質、鶏卵タンパク質、肉タンパク質などの動植物性タンパク質、これら加水分解物；バター、乳清ミネラル、クリーム、ホエイ、非タンパク態窒素、シアル酸、リン脂質、乳糖などの各種乳由来成分などが挙げられる。糖類、加工澱粉（デキストリンのほか、可溶性澱粉、ブリティッシュスターチ、酸化澱粉、澱粉エステル、澱粉エーテルなど）、食物繊維などが挙げられる。脂質としては、例えば、ラード、魚油など、これらの分別油、水素添加油、エステル交換油などの動物性油脂；パーム油、サフラワー油、コーン油、ナタネ油、ヤシ油、これらの分別油、水素添加油、エステル交換油などの植物性油脂などが挙げられる。ビタミン類としては、例えば、ビタミンＡ、カロチン類、ビタミンＢ群、ビタミンＣ、ビタミンＤ群、ビタミンＥ、ビタミンＫ群、ビタミンＰ、ビタミンＱ、ナイアシン、ニコチン酸、パントテン酸、ビオチン、イノシトール、コリン、葉酸などが挙げられ、ミネラル類としては、例えば、カルシウム、カリウム、マグネシウム、ナトリウム、銅、鉄、マンガン、亜鉛、セレンなどが挙げられる。有機酸としては、例えば、リンゴ酸、クエン酸、乳酸、酒石酸などが挙げられる。これらの成分は、２種以上を組み合わせて使用することができ、合成品および／またはこれらを多く含む食品を用いてもよい。 When the amino acid composition of the present invention is used for food and drink, the other ingredients are not particularly limited, but the food and drink may be water, protein, carbohydrate, lipid, vitamins, minerals, organic acid, Organic bases, fruit juice, flavors and the like can be used as ingredients. Examples of proteins include whole milk powder, skimmed milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, β-lactoglobulin , Α-lactalbumin, lactoferrin, soy protein, egg protein, animal protein such as meat protein, hydrolysates of these, butter, whey mineral, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose etc And various milk-derived components of Examples thereof include saccharides, modified starches (dextrin, soluble starch, British starch, oxidized starch, starch esters, starch ethers and the like), dietary fiber and the like. Examples of lipids include animal fats and oils such as lard and fish oil, fractionated oils thereof, hydrogenated oils, transesterified oils and the like; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Vegetable oils and fats such as hydrogenated oils and transesterified oils may be mentioned. As vitamins, for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline And folic acid and the like, and as minerals, for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like can be mentioned. Examples of the organic acid include malic acid, citric acid, lactic acid and tartaric acid. These components can be used in combination of 2 or more types, and you may use the foodstuff which contains a synthetic product and / or these abundantly.
　本発明の食品、飲料、医薬品は、一態様において、容器詰めにしてよく、当該容器は、プラスチック、紙製、金属製、陶器製またはその複合素材などから選択されてもよい。これらの容器に詰めた容器詰めの形態にすることができる。すなわち、本発明のアミノ酸組成物を含有する、容器詰め飲食品、容器詰め医薬品が例示できる。また、プラスチック製のシュリンクフィルム、遮光フィルム（例えば、金属箔層フィルム、黒色または暗色インク塗布フィルムで、容器を被覆されてもよいし、前記容器や前記フィルムを二種類以上で組合せて用いてもよい。光透過や酸素透過による風味劣化および分解（減少）の観点から、遮光性のある容器やフィルムを組合せることが好ましい。 The food, beverage, and pharmaceutical product of the present invention may, in one aspect, be packaged in a container, which may be selected from plastic, paper, metal, pottery or composite materials thereof. It can be in the form of a container packed in these containers. That is, a container-packed food / drink product, a container-packed pharmaceutical containing the amino acid composition of the present invention can be exemplified. In addition, the container may be covered with a plastic shrink film, a light shielding film (for example, a metal foil layer film, a black or dark ink applied film, or the container or the film may be used in combination of two or more types. From the viewpoint of taste deterioration and decomposition (reduction) by light transmission and oxygen transmission, it is preferable to combine a light-shielding container or film.
　本発明のアミノ酸組成物または飲食品は、一食あたりの単位包装形態からなり、当該単位包装形態中に、アルギニン、バリンおよびセリンを含む。ここで、「一食あたりの単位包装形態」からなるとは、一食あたりの摂取量があらかじめ定められた形態のものであり、例えば、特定量を経口摂取し得る飲食品として、一般食品のみならず、飲料（ドリンク剤など）、健康補助食品、保健機能食品、サプリメントなどの形態を意味する。「一食あたりの単位包装形態」では、例えば、液状の飲料、ゲル状、糊状、若しくはペースト状のゼリー、粉末状、顆粒状、カプセル状、若しくはブロック状の固体状の食品などの場合には、金属缶、ガラスビン（ボトルなど）、プラスチック容器（ペットボトルなど）、パック、パウチ、フィルム容器、紙箱などの包装容器で特定量（用量）を規定できる形態、あるいは、一食あたりの摂取量（用法、用量）を包装容器やホームページなどに表示することで特定量を規定できる形態が挙げられる。 The amino acid composition or food and drink of the present invention is in unit package form per serving, and contains arginine, valine and serine in the unit package form. Here, "consisting of" unit packaging form per serving "means that the intake per serving is previously determined, and for example, as a food and drink that can orally ingest a specific amount, not only general food but also It means forms such as beverages (drinks etc.), health supplements, health functional foods, supplements and the like. In the “unit packaging form per serving”, for example, in the case of liquid beverages, gel-like, paste-like or paste-like jelly, powder-like, granular, capsule-like or block-like solid food etc. , A form that can specify a specific amount (dose) in packaging containers such as metal cans, glass bottles (such as bottles), plastic containers (such as plastic bottles), packs, pouches, film containers, paper boxes, etc. , A dose) can be specified on a packaging container, a home page or the like to specify a specific amount.
　本発明のアミノ酸組成物または飲食品の１日あたりの摂取量は、運動、年齢、性別、体重、食事の状況などに基づき、個別に定められる。
　本発明のアミノ酸組成物、それを含む食品、飲料または医薬品は、運動パフォーマンスの向上が期待できるので、運動習慣のない人、スポーツ愛好家、アスリート、肥満予備軍、肥満、メタボリックシンドロームの患者や動物、競走用の動物などに好ましく使われる。 The daily intake of the amino acid composition or the food and drink of the present invention is individually determined based on exercise, age, sex, body weight, dietary condition and the like.
The amino acid composition of the present invention and foods, beverages or medicines containing it can be expected to improve exercise performance, so people without sports habits, sports enthusiasts, athletes, obese reserve forces, obesity, patients and animals with metabolic syndrome It is preferably used for race animals and the like.
　本発明のアミノ酸組成物または飲食品は、ノルアドレナリンの分泌促進によって、運動パフォーマンスが向上することに効果的であることを示す表示が付されたもの、好ましくは、交感神経の活性化、集中力の向上、疲労の予防、疲労の改善、疲労の軽減、疲労の緩和、糖代謝亢進、脂質代謝亢進、脂肪の分解、脂質代謝の改善、運動パフォーマンスの向上が期待できることから、例えば、筋力の向上、瞬発力の向上、スタミナ、持久力の向上、体が軽く感じられる、運動の後半まで体力を残せる、集中力が維持できる、体の疲れが少ない、バテを抑える、きつさを抑える、しっかりトレーニングできる、スポーツ（運動）を楽しむことができる、理想のパフォーマンスが発揮できる、楽に動ける、いつものパフォーマンスの限界を超えられるなど効果的であることを示す表示が付されたものであってもよい。 The amino acid composition or food / drink product of the present invention is preferably labeled with an indication that it is effective in enhancing exercise performance by promoting secretion of noradrenaline, preferably sympathetic nerve activation, concentration Improvement, prevention of fatigue, improvement of fatigue, reduction of fatigue, reduction of fatigue, enhancement of glucose metabolism, increase in lipid metabolism, degradation of fat, improvement of lipid metabolism, improvement of exercise performance, for example, improvement of muscle strength, Ability to improve instantaneous power, stamina, endurance, feel lighter, maintain strength until the second half of the exercise, maintain concentration, reduce body fatigue, reduce sagging, reduce tightness, firmly train Can enjoy sports (exercise), can perform ideal performance, can move easily, and exceeds the usual performance limits Or it may be displayed attached indicating the Runado effective.
　ここで、本発明の表示は、ノルアドレナリンの分泌促進用アミノ酸組成物に関連して付したものであれば、とくに限定されず、例えば、ノルアドレナリンの分泌促進用アミノ酸組成物、食品、飲料、医薬品を含有する容器、包装材または添付文書に、組成物が効果的である表示・広告などを付したものであってもよい。また、本発明の表示は、例えば、チラシ、パンフレット、ポップ、カタログ、ポスター、書籍、ＤＶＤなどの記憶媒体、電子掲示板やインターネットなどの広告などに、組成物が効果的である表示・広告などを付したものであってもよい。さらに、本発明の表示と同などの内容を、商談および／または販売促進を目的に、口頭および／または録音・録画した記録媒体からの再生で第三者に伝達することができる。 Here, the display of the present invention is not particularly limited as long as it is attached in relation to the amino acid composition for promoting norepinephrine secretion, for example, an amino acid composition for promoting noradrenaline secretion, food, beverage, medicine The container, the packaging material, or the package insert that is contained may be provided with a display, an advertisement, etc. that the composition is effective. In addition, the display of the present invention is, for example, a display, advertisement, etc. in which the composition is effective for storage media such as flyers, brochures, pops, catalogs, posters, books, books, DVDs, etc. It may be attached. Furthermore, the same content as the display of the present invention can be transmitted to a third party by reproduction from a verbal and / or recorded / recorded recording medium for the purpose of business talk and / or promotion.
　本発明のノルアドレナリンの分泌促進用アミノ酸組成物、食品、飲料、医薬品の製造にあたって、上記アミノ酸を使用して、これらを混合すればよい。また飲料とする場合にはこれらを、蒸留水などに混合して溶解すればよい。 The amino acids for promoting secretion of noradrenaline according to the present invention, foods, beverages, and medicaments may be mixed using the above amino acids. Moreover, what is necessary is just to mix and melt | dissolve in distilled water etc., when setting it as a drink.
　以下、実施例を示して、本発明をさらに具体的に説明するが、本発明の範囲は、これら実施例の記載に何ら限定されるものではない。 EXAMPLES Hereinafter, the present invention will be more specifically described by way of examples. However, the scope of the present invention is not limited to the description of these examples.
例１：アミノ酸組成物の調製（カプセル入り）
　カプセル５粒中、Ｌ－アルギニン１８００ｍｇ、Ｌ－バリン１１００ｍｇ、Ｌ－セリン１００ｍｇとなるように、Ｌ－アルギニン、Ｌ－バリンおよびＬ－セリンの混合物をセルロースホワイトカプセル００号（株式会社松屋製）に充填し、カプセル入りアミノ酸組成物（実施例１）を調製した。なお、Ｌ－アルギニン、Ｌ－バリンおよびＬ－セリンは、協和発酵バイオ株式会社製である。 Example 1: Preparation of amino acid composition (encapsulated)
A mixture of L-arginine, L-valine and L-serine was added to Cellulose White Capsule No. 00 (Matsuya Co., Ltd.) so that L-arginine 1800 mg, L-valine 1100 mg, L-serine 100 mg in 5 capsules. It filled and the encapsulated amino acid composition (Example 1) was prepared. L-arginine, L-valine and L-serine are manufactured by Kyowa Hakko Bio Co., Ltd.
例２：運動試験
　本発明のアミノ酸組成物を摂取した場合の運動試験を行った。試験系の概要を図１に示す。
　試験食品として、被験食品（実施例１のカプセル入りアミノ酸組成物）および対照食品（外観からの識別を不可能にして二重盲検性を維持するために、被験食品と同様にセルロースホワイトカプセル００号（株式会社松屋製）５粒にデキストリン３０００ｍｇを入れたもの（比較例１））を用いた。 Example 2: Exercise Test An exercise test was conducted when the amino acid composition of the present invention was ingested. The outline of the test system is shown in FIG.
Test food (encapsulated amino acid composition of Example 1) and control food (capsulated amino acid composition of Example 1) and control food (not distinguishable from appearance to maintain double-blindness, cellulose white capsule similar to test food 00) No. 5 (manufactured by Matsuya Co., Ltd.) containing 3000 mg of dextrin (Comparative Example 1)) was used.
　被験者（２０歳以上の健常人（男性１９名））を、スクリーニング時の年齢・体重を指標として、無作為に２群に分け、ダブルブラインド・クロスオーバー比較試験を行った。
　群１（９名）は、先に被験食品摂取試験を行い、その後６日間以上の間隔をあけて、対照食品摂取試験を行い、群２（１０名）は、先に対照食品摂取試験を行い、その後６日間以上の間隔をあけて、被験食品摂取試験を行った。 The subjects (healthy people over 20 years old (19 males)) were randomly divided into two groups using age and weight at screening as indicators, and a double blind crossover crossover test was conducted.
Group 1 (9) performs the test food intake test first, and then performs the control food intake test at intervals of 6 days or more, and group 2 (10) performs the control food intake test first Then, at intervals of 6 days or more, test food intake test was conducted.
　試験食品は１日２回、１回３０００ｍｇの摂取を３日間続け、３日目に運動試験を実施した（図１）。運動試験前日の夕食は規定食とし、１２．５～１５．５時間の絶食時間を挟んで、運動試験当日に糖質ゼリーを摂取した。糖質ゼリー摂取の１時間後に試験食品の１回目摂取を行い、試験食品１回目摂取の１０分後から１０分間の自転車エルゴメーター（エアロバイク（登録商標）７５ＸＬIII（株式会社コナミスポーツライフ製）によるウォームアップを行い、試験食品１回目摂取の３０分後から以下の持久運動を実施した。
　持久運動では５０％ＶＯ２ｐｅａｋ強度で４５分間の運動を１５分間の間隔を挟んで２回実施し、１回目の５０％ＶＯ２ｐｅａｋ強度運動の終了時に試験食品の２回目摂取を行った。 The test food was consumed twice daily at a dose of 3000 mg for 3 days, and the exercise test was performed on the 3rd day (FIG. 1). The dinner on the day before the exercise test was taken as a diet, and carbohydrate jelly was ingested on the day of the exercise test, with a fasting time of 12.5 to 15.5 hours. One hour after ingestion of the sugar jelly, the first intake of the test food is taken, and 10 minutes after the first intake of the test food by a bicycle ergometer (Aerobike (registered trademark) 75 XL III (manufactured by Konami Sports Life Co., Ltd.) for 10 minutes Warm up was performed, and the following endurance exercise was performed 30 minutes after the first intake of the test food.
The endurance exercise was performed twice across the interval of the movement of 45 minutes at 50% VO 2peak strength 15 minutes to perform a second intake of the test food during the first 50% VO 2peak intensity exercise ends.
　持久運動終了５分後にWingate testを実施した。Wingate testは無酸素運動能力を評価する代表的な方法であり、本実験では体重の７．５％負荷で３０秒間全力ペダリングを行う条件で実施した。
　なお、上記の運動は全て自転車エルゴメーターを用いて実施した（ウォーミングアップ、持久運動はエアロバイク（登録商標）７５ＸＬIII（株式会社コナミスポーツライフ製）、Wingate testはパワーマックスＶIII（株式会社コナミスポーツライフ製）を使用した）。
運動試験当日には採血を６回（Ｓ１：糖質ゼリー摂取前、Ｓ２：持久運動開始時、Ｓ３：１回目の５０％ＶＯ２ｐｅａｋ強度運動の終了時、Ｓ４：持久運動終了時、Ｓ５：Wingate test終了５分後、Ｓ６：Wingate test終了２０分後）実施し、糖代謝・脂質代謝の血中指標を測定した。 Five minutes after the end of the endurance exercise, we conducted the Wingate test. The Wingate test is a representative method for evaluating anoxic exercise capacity, and in this experiment, it was performed under the condition of performing full power pedaling at a load of 7.5% of body weight for 30 seconds.
The above exercise was all carried out using a bicycle ergometer (warming up, endurance exercise: aerobic bike (registered trademark) 75 XL III (manufactured by Konami Sports Life Co., Ltd.), Wingate test: Powermax VIII (manufactured by Konami Sports Life Co., Ltd.) )It was used).
Exercise test day in bled six times (S1: sugar jelly before taking, S2: at endurance exercise starts, S3: 1 time 50% VO 2peak intensity during exercise of the end of, S4: At the end endurance exercise, S5: Wingate Five minutes after the end of the test, 20 minutes after the end of the S6: Wingate test) were carried out, and blood indicators of glucose metabolism and lipid metabolism were measured.
　血中アドレナリン濃度および血中ノルアドレナリン濃度は、ＨＰＬＣ（ＨＬＣ－７２５ＣＡII、東ソー株式会社）により測定した。血中アドレナリン濃度の測定結果を図２に示し、血中ノルアドレナリン濃度の測定結果を図３に示す。
　実施例１を摂取すると、比較例１の場合に比べ、運動中の血中アドレナリン濃度および血中ノルアドレナリン濃度が上昇した。とくに、血中ノルアドレナリン濃度がＳ３（１回目の５０％ＶＯ２ｐｅａｋ強度運動の終了時）、Ｓ４（持久運動終了時）、Ｓ５（Wingate test終了５分後）の間において有意に高値で推移した。 Blood adrenaline concentration and blood noradrenaline concentration were measured by HPLC (HLC-725CAII, Tosoh Corporation). The measurement results of blood adrenaline concentration are shown in FIG. 2, and the measurement results of blood noradrenaline concentration are shown in FIG.
When Example 1 was ingested, compared to Comparative Example 1, blood adrenaline and blood noradrenaline concentrations during exercise increased. In particular, (at the end of the first 50% VO 2peak intensity exercise) blood noradrenaline concentrations S3, S4 (at the end of endurance exercise), remained at significantly higher during the S5 (Wingate test completion after 5 minutes).
　実施例１を摂取すると、比較例１の場合に比べ、Wingate testにおけるピークパワーが高くなる傾向が見られた。Ｓ５（Wingate test終了５分後）の血中ノルアドレナリン濃度とWingate testのパフォーマンスには正の相関がみられた（図４）。
　実施例１を摂取した場合、比較例１を摂取した場合に比べ、血中アドレナリン濃度および血中ノルアドレナリン濃度が高くなり、運動パフォーマンスが向上した。 When the Example 1 was ingested, the peak power in the Wingate test tended to be higher than in the Comparative Example 1. There was a positive correlation between the blood noradrenaline concentration of S5 (5 minutes after completion of Wingate test) and the performance of Wingate test (FIG. 4).
When Example 1 was ingested, compared with the case of ingesting Comparative Example 1, blood adrenaline concentration and blood noradrenaline concentration became higher, and exercise performance was improved.
例３：アミノ酸組成物の保存性
　Ｌ－アルギニン１８００ｍｇ、Ｌ－バリン１１００ｍｇ、Ｌ－セリン１００ｍｇをセルロースホワイトカプセル００号に充填し、カプセル入りアミノ酸組成物を製造し、アルミパウチ容器に充填した。室温保存２週間後におけるカプセル内のアミノ酸含有組成物は分解（減少）することなく保持された。 Example 3: Storage of amino acid composition 1800 mg of L-arginine, 1100 mg of L-valine and 100 mg of L-serine were filled in Cellulose White Capsule No. 00 to prepare a capsuled amino acid composition and filled in an aluminum pouch container. The amino acid-containing composition in the capsule after 2 weeks of storage at room temperature was retained without decomposition (reduction).
　本発明のアミノ酸組成物は、ノルアドレナリンの分泌を促進する効果を有し、アドレナリンの分泌を促進する傾向があり、運動パフォーマンスや運動に対するモチベーションを向上することができる。これにより、運動量の少ない人が運動を習慣的に実施する可能性や、運動愛好家やアスリートが運動パフォーマンスを維持、向上するための食品を設計できる。このとき、日本人の健康寿命の延伸に繋がり、この結果として、医療費の低減等で、社会に大きく貢献できる。 The amino acid composition of the present invention has the effect of promoting the secretion of noradrenaline, tends to promote the secretion of adrenalin, and can improve exercise performance and motivation for exercise. As a result, people with less exercise can practice exercise routinely, and food for exercise enthusiasts and athletes to maintain and improve exercise performance can be designed. At this time, it leads to the extension of the healthy life span of the Japanese, and as a result, it is possible to greatly contribute to society by reducing medical expenses and the like.

Claims (9)

  1. 　アルギニン、バリンおよびセリンからなるノルアドレナリンの分泌促進用アミノ酸組成物。 An amino acid composition for promoting secretion of noradrenaline, which comprises arginine, valine and serine.
  2. 　アルギニン、バリンおよびセリンの重量比が、５０～７０：２５～５０：０．１～１５である、請求項１に記載のアミノ酸組成物。 The amino acid composition according to claim 1, wherein the weight ratio of arginine, valine and serine is 50-70: 25-50: 0.1-15.
  3. 　アルギニン、バリンおよびセリンの重量比が、１０～２８：７～２２：１である、請求項１に記載のアミノ酸組成物。 The amino acid composition according to claim 1, wherein the weight ratio of arginine, valine and serine is 10-28: 7-221.
  4. 　可食性容器に詰められてなる、請求項１～３のいずれか一項に記載のアミノ酸組成物。 The amino acid composition according to any one of claims 1 to 3, which is packed in an edible container.
  5. 　請求項１～４のいずれか一項に記載のアミノ酸組成物を有効量で含む、ノルアドレナリンの分泌促進用の食品、飲料または医薬品。 A food, beverage or medicine for promoting the secretion of noradrenaline, which comprises the amino acid composition according to any one of claims 1 to 4 in an effective amount.
  6. 　アルギニン、バリンおよびセリン以外のアミノ酸を非有効量で含む、請求項５に記載の食品、飲料または医薬品。 The food, beverage or medicine according to claim 5, which comprises ineffective amounts of amino acids other than arginine, valine and serine.
  7. 　さらに、アミノ酸ではないアドレナリンおよび／またはノルアドレナリンの分泌促進用の有効成分を含む、請求項５または６に記載の食品、飲料または医薬品。 The food, beverage or medicine according to claim 5 or 6, further comprising an active ingredient for promoting secretion of adrenaline and / or noradrenaline which is not an amino acid.
  8. 　容器に詰められてなる、請求項５～７のいずれか一項に記載の食品、飲料または医薬品。 The food, beverage or medicine according to any one of claims 5 to 7, which is packed in a container.
  9. 　アルギニン、バリンおよびセリンを混合することを含む、請求項１～４のいずれか一項に記載のアミノ酸組成物または請求項５～８のいずれか一項に記載の食品、飲料または医薬品の製造方法。 The amino acid composition according to any one of claims 1 to 4, which comprises mixing arginine, valine and serine, or the method for producing a food, beverage or medicine according to any one of claims 5 to 8. .
PCT/JP2018/028197 2017-07-28 2018-07-27 Noradrenalin secretion promoting amino acid composition WO2019022219A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-146546 2017-07-28
JP2017146546A JP2019026584A (en) 2017-07-28 2017-07-28 Amino acid compositions for enhancing noradrenaline secretion

Publications (1)

Publication Number Publication Date
WO2019022219A1 true WO2019022219A1 (en) 2019-01-31

Family

ID=65040802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/028197 WO2019022219A1 (en) 2017-07-28 2018-07-27 Noradrenalin secretion promoting amino acid composition

Country Status (3)

Country Link
JP (1) JP2019026584A (en)
TW (1) TW201909891A (en)
WO (1) WO2019022219A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336432A (en) * 1993-05-28 1994-12-06 Rikagaku Kenkyusho Adrenaline and noradrenaline secretion promoting composition
JP2001187736A (en) * 1999-10-20 2001-07-10 Ito En Ltd Nutritive analeptic and nutritive analeptic drink

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336432A (en) * 1993-05-28 1994-12-06 Rikagaku Kenkyusho Adrenaline and noradrenaline secretion promoting composition
JP2001187736A (en) * 1999-10-20 2001-07-10 Ito En Ltd Nutritive analeptic and nutritive analeptic drink

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety", NUTRITIONAL NEUROSCIENCE, vol. 8, no. 3, 2005, pages 155 - 160, ISSN: 1028-415X *
ARNOLD, JEFF ET AL.: "Thermogenic and hormonal responses to amino acid infusion in septic humans", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 263, no. 1, 1992, pages E129 - E135, ISSN: 0002-9513 *
CHANYACHUKUL,THIDA ET AL.: "Attenuation of paraquat-indeced motor behavior and neurochemical disturbances by L-valine in vivo", TOXICOLOGY LETTERS, vol. 150, no. 3, 2004, pages 259 - 269, ISSN: 0378-4274 *
KIMBER J. ET AL.: "Cardiovascular and neurohormonal responses to i.v. 1-arginine in two groups with primary autonomic failure", JOURNAL OF NEUROLOGY, vol. 248, no. 12, 2001, pages 1036 - 1041, ISSN: 0340-5354 *
LECHIN, FUAD ET AL.: "The Effects of Oral Arginine on Neuroautonomic Parameters in Healthy Subjects", JOURNAL OF APPLIED RESEARCH, vol. 6, no. 3, 2006, pages 201 - 213, ISSN: 1537-064X *
TAKALA J. ET AL.: "Changes in respiratory control induced by amino acid infusions", CRITICAL CARE MEDICINE, vol. 16, no. 5, 1988, pages 465 - 469, ISSN: 0090-3493 *
TANCHEVA L. P. ET AL.: "New L-Valine peptide mimetics as potential neuropharmacological agents", BULGARIAN CHEMICAL COMMUNICATIONS, vol. 44, no. 1, 2012, pages 262 - 266, ISSN: 0324-1130 *
UEDA KEISUKE ET AL.: "Combination of aerobic exercise and an arginine, alanine, and phenylalanine mixture increases fat mobilization and ketone body synthesis", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 81, no. 7, March 2017 (2017-03-01), pages 1417 - 1424, ISSN: 1347-6947 *

Also Published As

Publication number Publication date
JP2019026584A (en) 2019-02-21
TW201909891A (en) 2019-03-16

Similar Documents

Publication Publication Date Title
EP2156751B1 (en) Novel sweetener having sugar-like taste and production method and use of the same
JP5876205B2 (en) Method for improving deficiency of sweetness of D-sorbose in sweetener comprising D-sorbose and improving sweetness persistence
JP5507802B2 (en) Muscle aging inhibitor
CN101394756A (en) Food and beverage products with improved taste impressions
US20120021088A1 (en) Oral use
MX2014007675A (en) Methods for using rebaudioside c as a flavor enhancer.
CA2773134A1 (en) Sweetness enhancers including rebaudioside a or d
US7223417B2 (en) Nutrient formulations
US20150087679A1 (en) Nutritional sleep supplement
JP5749880B2 (en) Body fat accumulation improving agent and metabolic syndrome improving agent comprising D-tagatose as an active ingredient
CN108697679B (en) Amino acid-containing composition
WO2009154280A1 (en) Agent for preventing excessive appetite
JP2008120754A (en) Antifatigue agent
JP4915959B2 (en) Novel sweetener with sugar-like taste, production method and use thereof
WO2019022219A1 (en) Noradrenalin secretion promoting amino acid composition
WO2019022216A1 (en) Amino acid composition for muscle strength improvement
JP4847732B2 (en) Cold remedy
JP7462338B2 (en) Anti-fatigue
JP7083254B2 (en) Food and beverage composition with reduced bitterness of β-hydroxy-β-methylbutyrate calcium salt (HMBCa)
US20060258746A1 (en) Oral medicament for improvement in going to sleep or waking
WO2003070021A1 (en) Nutritionally enriched maple syrup
US20050003047A1 (en) Intestinal mineral absorption capacity improver
JP5943516B2 (en) Sweetener for improving biological function comprising D-sorbose as an active ingredient
JP2017008002A (en) Anti-fatigue agent
JP2022151695A (en) Beverages containing iron compounds and ceramides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18837830

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18837830

Country of ref document: EP

Kind code of ref document: A1